Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Exome Recapture and Sequencing of Prospectively-Characterized Clinical Specimens

ABSTRACT: Exome Recapture and Sequencing of Prospectively-Characterized Clinical Specimens

PROVIDER: PRJNA521281 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Exome Recapture and Sequencing of Prospectively-Characterized Clinical Specimens

Project description:Exome Recapture and Sequencing of Prospectively-Characterized Clinical Specimens

| PRJNA521280 | ENA

Anonymized germline variants of prospectively characterized clinical cancer specimens

Project description:Anonymized germline variants of prospectively characterized clinical cancer specimens

| PRJNA552120 | ENA

Anonymized germline variants of prospectively characterized clinical cancer specimens

Project description:Anonymized germline variants of prospectively characterized clinical cancer specimens

| PRJNA552121 | ENA

Exome Sequencing of Prospectively Characterized Clinical Specimens

Project description:<p>The study cohort comprises samples from patients whose tumors have been prospectively characterized as part of their care at Memorial Sloan Kettering Cancer Center. This includes a variety of distinct tumor type and molecular subtypes. </p>

| phs001783 | dbGaP

Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes

Project description:Despite the advancement of genomic classification of breast cancer, current clinical tests and treatment decisions are commonly based on protein level information. Formalin-fixed paraffin-embedded (FFPE) tissue specimens are widely available and can be directly linked to extended clinical outcomes. We performed comprehensive proteomic profiling of 300 FFPE breast cancer surgical specimens, 75 of each PAM50 subtype, with linked clinical outcomes. Using our highly sensitive SP3-Clinical Tissue Proteomics platform, we quantified 4214 proteins across all 300 samples. The analysis identified a distinct proteomic group characterized by high expression of immune response proteins and favorable survival rates. Four clinically distinct proteomic clusters within samples classified as triple negative breast cancer by immunohistochemistry had features of “basal-immune hot”, “basal-immune cold”, “mesenchymal”, and “luminal androgen receptor”. Our proteomic analysis characterizes the heterogeneity of breast cancer in a clinically-applicable manner, identifies potential biomarkers and therapeutic targets, and provides a resource for clinical breast cancer classification.

2022-02-22 | PXD024322 | Pride

Whole Exome Sequencing of Bladder Cancer Clinical Cohorts

Project description:Whole Exome Sequencing of Bladder Cancer Clinical Cohorts

| PRJNA254087 | ENA

Clinical Sequencing: Whole Exome Sequencing of CLL8 Cohort

Project description:Clinical Sequencing: Whole Exome Sequencing of CLL8 Cohort

| PRJNA285277 | ENA

Prostate specimens from a clinical trial of genistein supplementation prior to prostatectomy

Project description:Prostate specimens from a clinical trial of genistein supplementation prior to prostatectomy

| PRJNA331011 | ENA

Expression data from ccRCC specimens

Project description:To identify a therapeutic candidate target molecule for ccRCC, we analyzed the microRNA (miRNA) expression signatures in ccRCC clinical specimens.

2014-02-20 | GSE55138 | GEO

A cancer avatar models prospectively guides therapy

Project description:A cancer avatar models prospectively guides therapy

| PRJNA475104 | ENA